Lv27
156 积分 2023-12-20 加入
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
1小时前
已完结
Immune checkpoint inhibitors as neoadjuvant therapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis
11小时前
已完结
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
6天前
已完结
Lessons from neoadjuvant immunotherapy in melanoma: understanding antitumour immunity and tumour escape
16天前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
22天前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
22天前
已完结
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
22天前
已完结
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
22天前
已完结
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
22天前
已完结
Approvals by the China NMPA in 2025
25天前
已完结
皖公网安备34019202002308
